Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
A South African-based biopharmaceutical company has completed a licensing and technology transfer agreement with the non-profit international organisation International Vaccine Institute (IVI, Seoul, South Korea) in order to manufacture of an oral cholera vaccine.
Biovac, a biopharmaceutical company created through a partnership with the South African government in 2003, was established in response to a lack of human vaccine manufacturing capabilities on the African continent. The licensing and technology transfer project will fill a crucial step in the vaccine manufacturing value chain in the African vaccine manufacturing sector by providing drug substance manufacturing capabilities and the production of antigens/raw materials required in vaccine manufacturing. In partnership with IVI, Biovac aims to license and transfer technology to increase vaccine production volumes to respond to a shortage of cholera vaccines required not only in the continent of Africa, but globally. The project will also aim to demonstrate a capacity for GMP scale-up, as well as local manufacturing of clinical trial products and end-to-end vaccine production in Africa.
Cholera remains an ongoing issue for nations such as Pakistan, Nigeria, and Malawi, further aggravated by climate change, armed conflicts, and displacement. With a limited supply of global cholera vaccines, outbreaks in recent years have increased to the point where there remains a significant gap between the supply and demand for vaccines. CEO of Biovac, Morena Makhoana, stated: “It became clear that increasing self-sufficiency is important if Africa is to have better control over its own public health and vaccine supply chains.” Some African leaders have committed to the creation of an indigenous vaccine industry, with hopes of boosting vaccine manufacturing shares to 60% in 2040.
IVI’s Cholera Program Director Julia Lynch stated: “Oral cholera vaccine is a proven, highly effective measure against a disease that strikes the most vulnerable... We are thrilled to partner with Biovac to complete a technology transfer of [oral cholera vaccine] that will add another manufacturer to the marketplace and expand production capacity.”
“This initiative will be the beginning of end-to-end manufactur[ing] at Biovac, while at the same time addressing an ongoing and increasing cholera disease burden globally. In addition, this feeds directly into Biovac’s facilities expansion plan to scale up production capacity and will most likely be the first product (drug substance and drug product) to be manufactured in our new facility when it comes on line,” Makhoana commented.
The project is set to comment in January 2023, with clinical trial batches to be produced in 2024. Licensing is aimed to conclude in 2026 by the South African National Regulatory Authority along with the WHO Prequalification certification. It is collectively supported by the Wellcome Trust and the Bill & Melinda Gates Foundation totalling USD $6.9 million.
Source: Biovac-IVI-OCV-Technology-Transfer-Press-Release-23-Nov-2022.pdf
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance